Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure

Figure 1 Changes in renal-function-related indexes in the patients before and after treatment. A: Comparison of uric acid changes in the two groups before and after treatment; B: Comparison of serum creatinine changes in the two groups before and after treatment; C: Comparison of blood urea nitrogen changes in the two groups before and after treatment. ^aP < 0.05, ^bP < 0.01 ^cP < 0.001, ^dP < 0.0001. SCr: Serum creatinine; UA: Uric acid; BUN: Blood urea nitrogen.

Figure 2 Changes in bone-metabolism-related indexes in patients before and after treatment. A: Comparison of phosphorus changes before and after treatment; B: Comparison of calcium changes before and after treatment; C: Comparison of procollagen type I amino-terminal propeptide changes before and after treatment; D: Comparison of intact Paricalcitol hormone changes before and after treatment. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, ^dP < 0.0001. PINP: Procollagen type I amino-terminal propeptide; iPTH: intact Paricalcitol hormone.

Figure 3 Least absolute shrinkage and selection operator-based screening of predictors. A, B: The coefficient distribution of the least absolute shrinkage and selection operator repression analysis and the calculation of adjustment parameters (lambda) based on partial likelihood deviation of 10 times cross-validation.

Figure 4 Risk score in patients with different efficacy. A: Risk score in the non-improvement group and improvement group; B: Receiver operating characteristic curve of risk score in predicting efficacy. ^dP < 0.0001.